EXHIBIT 7.1
February 21, 2019
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Commissioners:
We have read the statements made by Eidos Therapeutics, Inc. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01(a) and 4.02(b) of Form8-K, as part of the Form8-K of Eidos Therapeutics, Inc. dated February 15, 2019. We agree with the statements concerning our Firm disclosed under Items 4.01(a) and 4.02(b) in such Form8-K.
Very truly yours,
/s/ PricewaterhouseCoopers LLP
San Jose, California